After Evercore ISI and Piper Sandler gave Ventyx Biosciences (NASDAQ: VTYX) a Buy rating last month, the company received another Buy, this time from Jefferies. Analyst Michael Yee maintained a Buy rating on Ventyx Biosciences yesterday and set a price target of $30.00. The company’s shares closed last Wednesday at $14.05.
According to TipRanks.com, Yee is a 1-star analyst with an average return of -2.0% and a 42.1% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Denali Therapeutics, and Aligos Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ventyx Biosciences with a $38.75 average price target, which is a 181.4% upside from current levels. In a report issued on March 25, Evercore ISI also maintained a Buy rating on the stock with a $45.00 price target.
The company has a one-year high of $26.00 and a one-year low of $9.50. Currently, Ventyx Biosciences has an average volume of 115.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Read More on VTYX: